Mr. Zhang Ruinian (张瑞年), aged 61, is an executive Director and the President of our Company. He is mainly responsible for participating in the total management and strategic development of our Group.

Mr. Zhang has over 20 years of experience in the fields of cardiovascular, general surgery, orthopedics, neurosurgery and neurovascular, in vitro diagnosis, diabetes and medical analytical instruments. From January 2023 to May 2024, Mr. Zhang served as the vice president of Jenscare Scientific Co., Ltd. (宁波健世科技股份有限公司), whose shares are listed on the Stock Exchange (stock code: 9877), where he also served as a consultant from July 2024 to March 2025. From April 2021 to December 2022, Mr. Zhang served as the general manager of the Greater China region at Corcym Medical Technology (Shanghai) Co., Ltd. (恪心医疗科技（上海）有限公司). From April 2018 to June 2020, he served as the chief executive director of Suzhou Jiecheng Medical Technology Co., Ltd. (苏州杰成医疗科技有限公司). Prior to that, he also held senior management positions in various well-known global and domestic companies, including Xi'an Janssen Pharmaceutical Co.,Ltd. (西安杨森制药公司), Rhone-Poulenc Rorer S.A (China) Limited (罗纳普朗克（中国）公司), Medtronic (China) Co., Ltd. (美敦力中国有限公司), Baxter Healthcare Co., Ltd., Edward Lifesciences Corporation (爱德华生命科学公司), Applied Biosystems Inc. (美国应用生物系统公司), Johnson & Johnson Medical (China) Ltd. (强生（中国）医疗器材有限公司), MicroPort Scientific Corporation (微创医疗科学有限公司), whose shares are listed on the Stock Exchange (stock code: 0853), Alcon Vision Products (China) Co., Ltd. (爱尔康（中国）眼科产品有限公司), among others. 

Mr. Zhang obtained his bachelor's degree in clinical medicine from the Shanghai Jiao Tong University School of Medicine (上海交通大学医学院) (formerly known as the Shanghai Second Medical University) (上海第二医科大学) in July 1987, and his master's degree in business administration from the University of British Columbia in January 2004.